SNDXSyndax Pharmaceuticals, Inc.

$2B

Q4 2018 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$380,000-68.1% YoY

Gross Profit

$380,000100.0% margin

Operating Income

-$19M-5087.6% margin

Net Income

-$19M-4957.1% margin

EPS (Diluted)

$-0.70

QoQ Revenue Growth

+0.3%

Cash Flow

Operating Cash Flow

-$15M

Free Cash Flow

-$15M

Stock-Based Comp.

$1M

Balance Sheet

Total Assets

$84M

Total Liabilities

$31M

Stockholders' Equity

$53M

Cash & Equivalents

$34M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$380,000	$1M	-68.1%
Gross Profit	$380,000	$1M	-68.1%
Operating Income	-$19M	-$19M	+0.8%
Net Income	-$19M	-$19M	+1.4%

SNDX Q4 2018 Earnings — Syndax Pharmaceuticals, Inc. Revenue & Financial Results | Market Cap Arena